HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 03/11/2013 -- CombiMatrix Corporation (NASDAQ:CBMX) is up over 32.19%. CombiMatrix is a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders. The company reported today that total revenues for the fourth quarter and full-year 2012, increased to $1.5 million and $5.4 million, respectively, up 18% and 15% from the fourth quarter and full-year 2011. Revenues from the Company’s core prenatal testing markets in the fourth quarter grew by 161% over the corresponding period in 2011 and grew by more than 101% for full-year 2012 over the comparable prior year. On a sequential basis, prenatal testing revenues in the 2012 fourth quarter grew by 76% over the 2012 third quarter.
Is CBMX Showing Any Sign of Buy At The Current Market Price? Find Out Here
PharmAthene, Inc. (NYSEAMEX:PIP) is taken a 11.73% gain in value. PharmAthene is a biodefense company developing medical countermeasures against biological and chemical threats. About a week ago the company entered into an exclusive commercial license for the use of Percivia’s proprietary PER.C6® technology platform in the production of PharmAthene’s next generation recombinant butyrylcholinesterase (rBChE) bioscavenger.
The PER.C6® platform is a human, cell-based manufacturing system that enables the production of high quality, cost effective biological products for the life sciences industry with the added benefit of being fully human, unlike products manufactured using other expression systems.
How Should Investors Trade PIP After Today’s Rally? Find Out Here
MannKind Corporation (NASDAQ:MNKD) gained +8.90% to $3.06 on Friday, seeming after Seeking Alpha provided 5 reasons why this stock could be the best performing stock of 2013.
At that price, the company has a market cap of $752.08million. The stock has a 52 week worst hit of $1.57 and a 52 week high of $3.11. The P/S ratio is 21882.06 and P/C ratio 412.87. The beta value is 1.06. MNKD’s RSI amounts to 75.81.
Is MNKD Showing Any Sign of Buy At The Current Market Price? Find Out Here
Zogenix, Inc. (NASDAQ:ZGNX) is +0.1185 - +6.66% from the previous close of $1.78. It traded between $1.75 - 2.00 with total traded volume of 1449600 shares. Keep a close eye on ZGNX, as the stock has been showing unusual moves over the past weeks. At Current market price, ZGNX has recovered +71.04% from its 52-week Low of 1.11 and has Pulled back -42.47% from its 52-week high of 3.30. Zogenix, Inc. is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain.
What Should Investors Do With ZGNX Now? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)